Cancer patients display diminished viral RNA clearance and altered T cell responses during SARS-CoV-2 infection
Clinical Cancer Research
; 27(6 SUPPL 1), 2021.
Article
in English
| EMBASE | ID: covidwho-1816919
ABSTRACT
Cancer patients display immunomodulation related to malignancy and anti-cancer therapies, but how these factors impact COVID-19 remains unknown. To investigate immune responses in cancer patients with COVID-19, we undertook a prospective case-control study, enrolling hospitalized solid tumor patients with acute COVID-19, as well as age-, gender-, and comorbidity-matched COVID-19 patients without cancer as controls. Using biospecimens collected during hospitalization, we performed virologic measurements as well as in-depth immunophenotyping of cellular, antibody and cytokine responses. We enrolled 17 cancer patients (cases) admitted to Yale-New Haven Hospital between March 15 and June 30, 2020 with COVID-19, as well as 17 matched non-cancer patients (controls) admitted with COVID-19. No significant differences were observed between cases and controls based on patient characteristics (age, gender, race, co-morbidities, smoking history, days from symptom onset to COVID-19 diagnosis) or outcomes (COVID-19 severity, length of hospital stay, rate of intubation or mortality). The most common primary tumor sites were lung (4/17) and gastrointestinal (4/17);all cases had received cancer-directed therapy within 6 months of COVID-19 diagnosis, with 13/17 receiving treatment less than 1 month prior to hospitalization. Three of 17 cases had received immune checkpoint inhibitor therapies. Despite having similar SARS-CoV-2 viral RNA loads at the time of COVID-19 diagnosis when compared with controls, cancer cases had increased viral RNA abundance during hospitalization, suggesting slower clearance. Antibody responses against SARS-CoV-2 were preserved in cancer cases, with cases displaying similar levels of IgM and IgG antibodies directed against SARS-CoV-2 epitopes compared to controls. Cytokine profiling revealed higher plasma levels of CCL3, IL1A and CXCL12 in cancer cases compared to controls. Using flow cytometric immunophenotyping, we found that innate immune and non-T cell adaptive immune parameters were similar between cases and controls hospitalized with COVID-19. However, among cancer cases on conventional therapies, T cell lymphopenia was more profound, and these cases demonstrated higher levels of CD8+ exhausted (CD8+CD45RA-PD1+TIM3+ ), CD8+GranzymeB+ and CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ activated T cells when compared with controls;interestingly, these differences were not observed in patients who had received immune checkpoint inhibition. Thus, we found reduced viral RNA clearance and specific alterations in T cell and cytokine responses in cancer patients hospitalized with COVID-19 compared with matched controls with COVID-19. This dysregulated T cell response in cancer patients, which may reflect immune modulation due to chronic antigen stimulation as well as cancer therapies, may lead to altered virologic and clinical outcomes in this population.
CD4 antigen; CD45RA antigen; cell antibody; cytokine; endogenous compound; epitope; HLA DR antigen; immune checkpoint inhibitor; immunoglobulin G antibody; immunoglobulin M; interleukin 1alpha; macrophage inflammatory protein 1alpha; stromal cell derived factor 1; virus RNA; adult; antibody response; cancer patient; cancer therapy; case control study; case report; clinical article; clinical outcome; comorbidity; conference abstract; coronavirus disease 2019; cytokine response; diagnosis; drug therapy; female; gender; gene expression; hospitalization; human; human cell; human tissue; immune response; immunoglobulin blood level; immunomodulation; immunophenotyping; immunostimulation; intubation; lung; lymphocytopenia; male; mortality; nonhuman; outcome assessment; primary tumor; prospective study; protein expression; protein fingerprinting; race; Severe acute respiratory syndrome coronavirus 2; smoking; solid malignant neoplasm; T lymphocyte
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Clinical Cancer Research
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS